Loading clinical trials...

Real-Life Outcomes of TAF/FTC/BIC in HIV Patients in Colombia | Clinical Trials | Clareo Health

COMPLETED

Real-Life Outcomes of TAF/FTC/BIC in HIV Patients in Colombia

Clinical Effectiveness, Adherence, Clinical and Paraclinical Outcomes Associated With Tenofovir Alafenamide/Emtricitabine/Bictegravir (TAF/FTC/BIC) in Patients Diagnosed With Human Immunodeficiency Virus HIV) in Colombia: A Real-Life Study

NCT06829082•Servicios de Salud IPS Suramericana S.A.S

View on ClinicalTrials.gov

Summary

HIV remains a major global health issue, with 38 million people affected, and significant challenges in diagnosis and treatment due to stigma and socioeconomic factors. In Colombia, the epidemic is concentrated among men who have sex with men, with 165,405 people living with HIV and 14,670 new cases reported in 2023. Barriers to treatment access are exacerbated by social factors and Venezuelan migration. While integrase inhibitors like TAF/FTC/BIC have shown effectiveness, real-world data in Colombia is limited. This study evaluates adherence, effectiveness, and clinical outcomes of TAF/FTC/BIC in 169 patients within the EPS SURA program, contributing context-specific evidence.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female patients aged 18 years or older.
•Individuals with a confirmed HIV diagnosis.
•Individuals enrolled in EPS SURA during the study period.
•Patients receiving treatment with the TAF/FTC/BIC regimen.

Exclusion Criteria

•Patients with a concurrent diagnosis of tuberculosis.
•Pregnant patients during the study period.
•Patients with virologic failure.
•Patients who started treatment with TAF/FTC/BIC but changed providers or discontinued treatment before completing six months of therapy.

Locations (1)

Servicios de Salud IPS Suramericana S.A.S.

Medellín, Antioquia, Colombia

Key Dates

Start Date

November 15, 2024

Primary Completion Date

January 17, 2025

Completion Date

January 17, 2025

Last Updated

February 17, 2025

Enrollment

161

ACTUAL participants

Conditions

HIV Treatment

Interventions

BIKTARVY 50Mg-200Mg-25Mg Tablet

DRUG

Addressing Drug Use Stigma in Human Immunodeficiency Virus (HIV) Care and Treatment Clinics in Tanzania

NCT04863898

Drug Use Stigma in HIV Treatment Clinics

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions